title: Antibody-Based Treatment of Acute Myeloid Leukemia.
abstract: While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.
authors.affiliation: Seattle Genetics, Inc., 21823-30th Drive Southeast, Bothell, WA, 98021, USA.
authors.forename: Phillip M
authors.initials: PM
authors.lastname: Garfin
authors.affiliation: Seattle Genetics, Inc., 21823-30th Drive Southeast, Bothell, WA, 98021, USA. efeldman@seagen.com.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Feldman
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000079982:Gemtuzumab; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D053650:Interleukin-3 Receptor alpha Subunit / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D016499:Radioimmunotherapy; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000276:immunology
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D053650:Interleukin-3 Receptor alpha Subunit; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab; C504717:SGN-30 monoclonal antibody
keywords: Acute myeloid leukemia; Antibody therapy; CD123; CD33; Immunotherapy